Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200831 | 0.86 | TLR8 (0.47) | TLR8CNR2 | |
| SCHEMBL9128868 | 0.82 | BCL2 (0.42) | — | |
| SCHEMBL5500478 | 0.82 | TLR8 (0.47) | TLR8 | |
| SCHEMBL6698577 | 0.81 | TLR8 (0.49) | TLR8 | |
| SCHEMBL560035 | 0.80 | TLR8 (0.48) | TLR8 | |
| SCHEMBL20694916 | 0.80 | TLR8 (0.48) | TLR8 | |
| SCHEMBL158196 | 0.80 | TLR8 (0.48) | TLR8 | |
| SCHEMBL9065394 | 0.80 | TLR8 (0.48) | TLR8 | |
| SCHEMBL3403921 | 0.80 | TLR8 (0.48) | TLR8 | |
| SCHEMBL11512512 | 0.77 | TLR8 (0.45) | TLR8BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273835-A1 | NOVEL COMPOUNDS | PROBIODRUG AG (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-2178830-A2 | NOVEL COMPOUNDS | Probiodrug AG (DE) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009007415-A2 | NOVEL COMPOUNDS | PROBIODRUG AG (DE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273835-A1 | NOVEL COMPOUNDS | IL6, PREP, PEPD | TLR8 2465/4885BCHE 565/4885TLR7 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.